Molecular docking studies of quercetin and its analogues against human inducible nitric oxide synthase
Tóm tắt
Nitric oxide synthases (NOS) catalyze to produce nitric oxide (NO) from L-arginine. The isoform of NOS i.e. inducible nitric oxide synthases (iNOS) expression is observed in various human malignant tumors such as breast, lung, prostate and bladder, colorectal cancer, and malignant melanoma. Also an increased level of iNOS expression and activity has been found in the tumor cells of gynecological malignancies, stroma of breast cancer and tumor cells of head and neck cancer. Because of its importance in causing tumors and cancer, iNOS enzyme has become a new target in finding novel inhibitors as anti cancer agents. The present work focuses on the molecular docking analysis of quercetin and its analogues against iNOS enzyme. Earlier there are reports of quercetin inhibiting iNOS enzyme in certain experiments as anti cancer agent. But the clinical use of quercetin is limited by its low oral bioavailability and therefore needed its molecular modification to improve its pharmacological properties. In the present study ten analogues of quercetin were found to be docked at the active site cavity with favorable ligand-protein molecular interaction and interestingly from the ADME-Toxicity analysis these analogues have enhanced pharmacological properties than quercetin.
Tài liệu tham khảo
Aaltoma SH, Lipponen PK, Kosma VM: Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001, 21: 3101-3106.
Aaltomaa SH, Lipponen PK, Viitanen J, Kankkunen JP, Ala-Opas MY, Kosma VM: The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int 2000, 86: 234-239. 10.1046/j.1464-410x.2000.00787.x
Advanced Chemistry Development, Inc: ACD/I-Lab, Version 2.0. Toronto, ON, Canada; 1994.
Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998, 58: 334-341.
Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC: p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998, 4: 1371-1376. 10.1038/3957
Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Sean MO, Harrington AM, Shields PG, Felley-Bosco E, Hussain SP, Harris CC: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999, 91: 86-88. 10.1093/jnci/91.1.86
Bolton E, Wang Y, Thiessen PA, Bryant SH Annual reports in computational chemistry. In PubChem: integrated platform of small molecules and biological activities. 4th edition. American Chemical Society, Washington, DC; 2008. chapt 12
Brennan PA, Moncada S: From pollutant gas to biological messenger: the diverse actions of nitric oxide in cancer. Ann R Coll Surg Engl 2002, 84: 75-78.
ChemOffice CambridgeSoft Corporation, 875 Massachusetts Ave, Cambridge, MA 02139, USA; 2010.
Chen YC, Shen SC, Lee WR, Hou WC, Yang LL, Lee TJ: Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 2001, 82: 537-548. 10.1002/jcb.1184
Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Nathan C: Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 1992, 176: 599-604. 10.1084/jem.176.2.599
Crowell JA, Steele VE, Sigman CC, Fay JR: Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003, 2: 815-823.
Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC: Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999, 6: 233-242. 10.1038/6675
Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC: Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996, 93: 2442-2447. 10.1073/pnas.93.6.2442
Franchi A, Gallo O, Paglierani M, Sardi I, Magnelli L, Masini E, Santucci M: Inducible nitric oxide synthase expression in laryngeal neoplasia: correlation with angiogenesis. Head Neck 2002, 24: 16-23. 10.1002/hed.10045
Freitas MP: MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners. Org Biomol Chem 2006, 4: 1154-1159. 10.1039/b516396j
Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998, 90: 587-596. 10.1093/jnci/90.8.587
García-Mediavilla V, Crespo I, Collado PS, Esteller A, Sánchez-Campos S, Tuñón MJ, González-Gallego J: The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol 2007, 557: 221-229. 10.1016/j.ejphar.2006.11.014
Garthwaite J, Boulton CL: Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995, 57: 683-706. 10.1146/annurev.ph.57.030195.003343
Gehlhaar DK, Verkhivker G, Rejto PA, Fogel DB, Fogel LJ, Freer ST: Docking Conformationally Flexible Small Molecules Into a Protein Binding Site Through Evolutionary Programming. Proceedings of the Fourth International Conference on Evolutionary Programming. Lect Notes Comput Sci 1995, 1447: 449-461.
Gehlhaar DK, Bouzida D, Rejto PA: Fully Automated And Rapid Flexible Docking of Inhibitors Covalently Bound to Serine Proteases. Proceedings of the Seventh International Conference on Evolutionary Programming. Springer-Verlag, London, UK; 1998:449-461.
Ghosh DK, Crane BR, Ghosh S, Wolan D, Gachhui R, Crooks C, Presta A, Tainer JA, Getzoff ED, Stuehr DJ: Inducible nitric oxide synthase: role of the N-terminal beta-hairpin hook and pterin-binding segment in dimerization and tetrahydrobiopterin interaction. EMBO J 1999, 18: 6260-6270. 10.1093/emboj/18.22.6260
Goodman JE, Hofseth LJ, Hussain SP, Harris CC: Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004, 44: 3-9. 10.1002/em.20024
Griffith OW, Stuehr DJ: Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 1995, 57: 707-736. 10.1146/annurev.ph.57.030195.003423
Hao XP, Pretlow TG, Rao JS, Pretlow TP: Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 2001, 61: 419-422.
Hayashi H, Kuwahara M, Fujisaki N, Furihata M, Ohtsuki Y, Kagawa S: Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Oncol Rep 2001, 8: 1275-1279.
Hickey MJ, Granger DN, Kubes P: Inducible nitric oxide synthase (iNOS) and regulation of leucocyte/endothelial cell interactions: studies in iNOS-deficient mice. Acta Physiol Scand 2001, 173: 119-126. 10.1046/j.1365-201X.2001.00892.x
James A, Crowell VES, Caroline CS, Judith RF: Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003, 2: 815-823.
Kinaci MK, Erkasap N, Kucuk A, Koken T, Tosun M: Effects of quercetin on apoptosis, NF-κB and NOS gene expression in renal ischemia/reperfusion injury. Exp Ther Med 2012, 3: 249-254.
Knowles RG, Moncada S: Nitric oxide synthases in mammals. Biochem J 1994, 298: 249-258.
Kojima M, Morisaki T, Tsukahara Y, Uchiyama A, Matsunari Y, Mibu R, Tanaka M: Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol 1999, 70: 222-229. 10.1002/(SICI)1096-9098(199904)70:4<222::AID-JSO5>3.0.CO;2-G
Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharm Toxicol Methods 2008, 44: 235-249.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997, 23: 3-25. 10.1016/S0169-409X(96)00423-1
Lirk P, Hoffmann G, Rieder J: Inducible nitric oxide synthase–time for reappraisal. Curr Drug Targets Inflamm Allergy 2002, 1: 89-108. 10.2174/1568010023344913
MacMicking J, Xie QW, Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 1997, 15: 323-350. 10.1146/annurev.immunol.15.1.323
Marletta MA, Hurshman AR, Rusche KM: Catalysis by nitric oxide synthase. Curr Opin Chem Biol 1997, 2: 656-663.
Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000, 6: 4739-4744.
Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M: Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001, 194: 194-200. 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S
Messmer UK, Ankarcrona M, Nicotera P, Brüne B: p53 expression in nitric oxide-induced apoptosis. FEBS Lett 1994, 355: 23-26. 10.1016/0014-5793(94)01161-3
Michal G: Biochemical pathways. John Wiley & Sons, New York; 1999.
Michel T, Feron O: Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997, 100: 2146-2152. 10.1172/JCI119750
Molegro APS: MVD 5.0 Molegro Virtual Docker. DK-8000 Aarhus C, Denmark; 2011.
Murakami A, Ashida H, Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett 2008, 269: 315-325. 10.1016/j.canlet.2008.03.046
Peng Y, Deng Z, Wang C: Preparation and prodrug studies of quercetin pentabenzensulfonate. Yakugaku Zasshi 2008, 128: 1845-1849. 10.1248/yakushi.128.1845
Rao CV: Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004, 555: 107-119. 10.1016/j.mrfmmm.2004.05.022
Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R: Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 2001, 68: 921-931. 10.1016/S0024-3205(00)00999-1
Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM: Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res 2005, 574: 124-138. 10.1016/j.mrfmmm.2005.01.028
Ropponen KM, Kellokoski JK, Lipponen PK, Eskelinen MJ, Alanne L, Alhava EM, Kosma VM: Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand J Gastroenterol 2000, 11: 1204-1211.
Sandau K, Pfeilschifter J, Brüne B: The balance between nitric oxide and superoxide determines apoptotic and necrotic death of rat mesangial cells. J Immunol 1997, 158: 4938-4946.
Schrödinger LLC: QikProp, version 3.5. New York, NY; 2012.
Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 1999, 161: 630-634. 10.1016/S0022-5347(01)61985-2
Thomsen R, Christensen MH: MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006, 49: 3315-3321. 10.1021/jm051197e
Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994, 54: 1352-1354.
Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995, 72: 41-44. 10.1038/bjc.1995.274
Ulrich B, Norman LA: Molecular mechanics (ACS Monograph 177). American Chemical Society, Washington, DC; 1982.
Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Härkönen P: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001, 29: 23-28.
Vakkala M, Kahlos K, Lakari E, Pääkkö P, Kinnula V, Soini Y: Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000, 6: 2408-2416.
van der Woude H, Alink GM, van Rossum BE, Walle K, van Steeg H, Walle T, Rietjens IM: Formation of transient covalent protein and DNA adducts by quercetin in cells with and without oxidative enzyme activity. Chem Res Toxicol 2005, 18: 1907-1916. 10.1021/tx050201m
Verschoyle RD, Steward WP, Gescher AJ: Putative cancer chemopreventive agents of dietary origin-how safe are they? Nature Cancer 2007, 59: 152-162. 10.1080/01635580701458186
Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker SA, Suzek TO, Wang J, Xiao J, Zhang J, Bryant SH: An overview of the PubChem BioAssay resource. Nucleic Acids Res 2010, 38: D255-D266. 10.1093/nar/gkp965
Weiming X, Li ZL, Marilena L, Mohamed A, Ian GC: The role of nitric oxide in cancer. Cell Res 2002, 12: 311-320. 10.1038/sj.cr.7290133
Xu W, Charles IG, Moncada S, Gorman P, Sheer D, Liu L, Emson P: Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the pericentric region of chromosome 17 and to chromosome 7, respectively. Genomics 1994, 21: 419-422. 10.1006/geno.1994.1286
Yagihashi N, Kasajima H, Sugai S, Matsumoto K, Ebina Y, Morita T, Murakami T, Yagihashi S: Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 2000, 436: 109-114. 10.1007/PL00008208
Yang JM, Chen CC: GEMDOCK: a generic evolutionary method for molecular docking. Proteins 2004, 55: 288-304. 10.1002/prot.20035